Aerovate Therapeutics, Inc. (AVTE)

Market Cap	567.29M
Revenue (ttm)	n/a
Net Income (ttm)	-75.52M
Shares Out	27.86M
EPS (ttm)	-2.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,313
Open	20.72
Previous Close	21.20
Day's Range	19.83 - 20.96
52-Week Range	9.41 - 32.42
Beta	1.23
Analysts	Strong Buy
Price Target	50.00 (+146.79%)
Earnings Date	May 13, 2024

About AVTE

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 30, 2021
• Employees: 51
• Stock Exchange: NASDAQ
• Ticker Symbol: AVTE

Analyst Forecast

According to 2 analysts, the average rating for AVTE stock is "Strong Buy." The 12-month stock price forecast is $50.0, which is an increase of 146.79% from the latest price.

Price Target

$50.0

(146.79% upside)

Analyst Consensus: Strong Buy